JP2021534750A5 - - Google Patents

Info

Publication number
JP2021534750A5
JP2021534750A5 JP2021509199A JP2021509199A JP2021534750A5 JP 2021534750 A5 JP2021534750 A5 JP 2021534750A5 JP 2021509199 A JP2021509199 A JP 2021509199A JP 2021509199 A JP2021509199 A JP 2021509199A JP 2021534750 A5 JP2021534750 A5 JP 2021534750A5
Authority
JP
Japan
Prior art keywords
sequence ids
sequence
cancer
antigen
ids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509199A
Other languages
English (en)
Japanese (ja)
Other versions
JP7488534B2 (ja
JP2021534750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/101659 external-priority patent/WO2020038379A1/en
Publication of JP2021534750A publication Critical patent/JP2021534750A/ja
Publication of JP2021534750A5 publication Critical patent/JP2021534750A5/ja
Application granted granted Critical
Publication of JP7488534B2 publication Critical patent/JP7488534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509199A 2018-08-20 2019-08-20 新規ながん免疫療法抗体組成物 Active JP7488534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720015P 2018-08-20 2018-08-20
US62/720,015 2018-08-20
PCT/CN2019/101659 WO2020038379A1 (en) 2018-08-20 2019-08-20 Novel cancer immunotherapy antibody compositions

Publications (3)

Publication Number Publication Date
JP2021534750A JP2021534750A (ja) 2021-12-16
JP2021534750A5 true JP2021534750A5 (cg-RX-API-DMAC7.html) 2022-08-22
JP7488534B2 JP7488534B2 (ja) 2024-05-22

Family

ID=69591356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509199A Active JP7488534B2 (ja) 2018-08-20 2019-08-20 新規ながん免疫療法抗体組成物

Country Status (12)

Country Link
US (1) US12391758B2 (cg-RX-API-DMAC7.html)
EP (1) EP3841126A4 (cg-RX-API-DMAC7.html)
JP (1) JP7488534B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210046725A (cg-RX-API-DMAC7.html)
CN (3) CN116063519B (cg-RX-API-DMAC7.html)
AU (1) AU2019324388A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003182A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110138A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002077A (cg-RX-API-DMAC7.html)
SG (1) SG11202101757QA (cg-RX-API-DMAC7.html)
TW (1) TW202016150A (cg-RX-API-DMAC7.html)
WO (1) WO2020038379A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250223361A1 (en) * 2022-04-01 2025-07-10 Mabtree Biologics Ag Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
CN118930652B (zh) * 2024-07-29 2025-03-11 北京肿瘤医院(北京大学肿瘤医院) 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101704734B1 (ko) * 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
BR112014012819B1 (pt) * 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
EP2863947B1 (en) * 2012-06-21 2018-03-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CA3175360C (en) * 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
TW201639891A (zh) * 2015-03-10 2016-11-16 索倫多醫療公司 結合psma之抗體治療劑
CN114853891A (zh) 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
ES2986360T3 (es) * 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1
US10059769B2 (en) * 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
CN106496327B (zh) * 2016-11-18 2019-01-15 昆山百尔泰生物科技有限公司 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体
CN108239149B (zh) * 2016-12-25 2021-03-05 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
CN107973854B (zh) * 2017-12-11 2021-05-04 苏州银河生物医药有限公司 Pdl1单克隆抗体及其应用
CA3117853A1 (en) * 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions

Similar Documents

Publication Publication Date Title
JP2022512043A5 (cg-RX-API-DMAC7.html)
JP2020524174A5 (cg-RX-API-DMAC7.html)
JP2021514664A5 (cg-RX-API-DMAC7.html)
RU2017105915A (ru) Антитела против pd-1
JP2019536430A5 (cg-RX-API-DMAC7.html)
JP2020529863A5 (cg-RX-API-DMAC7.html)
JP2020515239A5 (cg-RX-API-DMAC7.html)
JP2025124799A (ja) 細胞内部移行をモジュレートするための組成物および方法
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2017506067A5 (cg-RX-API-DMAC7.html)
JP2018502050A5 (cg-RX-API-DMAC7.html)
JP2021528047A5 (cg-RX-API-DMAC7.html)
JP2023546743A5 (cg-RX-API-DMAC7.html)
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
CN117946277A (zh) 多特异性抗体及其制备和使用方法
JP2020530770A5 (cg-RX-API-DMAC7.html)
JP2023543493A5 (cg-RX-API-DMAC7.html)
JP2021531255A5 (cg-RX-API-DMAC7.html)
JP2010509931A5 (cg-RX-API-DMAC7.html)
JP2022512891A5 (cg-RX-API-DMAC7.html)
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2021501567A5 (cg-RX-API-DMAC7.html)
CN115605513A (zh) 一种抗pd-l1和her2的双特异性抗体
Fan et al. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells
JP2021512652A5 (cg-RX-API-DMAC7.html)